Meta-analysis was conducted in a fixed/random effect model. Out of the 715 papers retrieved 12 studies (3605 cases and 5692 controls) on the association of CYP1B1 gene polymorphisms with endometrial cancer risk in different ethnic groups were identified. Meta-analysis was performed for CYP1B1 gene P005091 manufacturer polymorphisms: R48G (C/G, five studies), L432V
(C/G, 12 studies), N453S (A/G, four studies), and A119S (G/T, five studies). We did not detect any association of CYP1B1 gene A119S polymorphism with endometrial cancer. An association of CYP1B1 gene R48G polymorphism with endometrial cancer was found [GG vs. GC + CC: odds ratio (OR)= 0.55, 95% confidence interval (CI): 0.42-0.73, P < 0.0001; GG vs. CC: OR=0.46, 95% CI: 0.23-0.91, P=0.03]. We found that CYP1B1 gene L432V polymorphism was associated with a significantly increased risk of endometrial cancer (G vs. C: OR=1.23, 95% CI: 1.06-1.43, P=0.007; GC + GG vs. CC: OR=1.24, 95% CI: 1.08-1.43, P = 0.003; GC vs. CC: OR = 1.16, 95% CI: 1.04-1.29, P = 0.009). Moreover, we detected the association of CYP1B1 gene N453S polymorphism with endometrial cancer (G vs. A: OR = 0.82, 95% CI: 0.72-0.94, P = 0.005; GA vs. AA: OR = 0.81, 95% CI: 0.69-0.95,
P = 0.01). In conclusion, this meta-analysis provides strong evidence that CYP1B1 gene R48G, TH-302 molecular weight L432V, and N453S polymorphisms are associated SN-38 with endometrial cancer risk, but not A119S. European Journal of Cancer Prevention 20: 112-120 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.”
“Purpose: To evaluate the attitudes and perceptions of medical doctors and nurses in the Emergency Department ED towards the role of clinical pharmacists.
Methods: A pilot study was conducted among the medical and paramedical staff of the ED of
Public Hospital, Eastern Region, Saudi Arabia, Al-Ahsa, using a 24-item questionnaire on Doctor of Pharmacy (Pharm-D) program as well as clinical pharmacist and medical staff attitudes toward the availability and possible role of clinical pharmacist in EDs. The data analysed statistically.
Results: Sixteen of the 20 respondents expressed a willingness to participate in the study. Six (37.5 %) of the respondents were doctors while the rest were nursing staff. Ten (62.5 %) of the ED staff were aware of the professional degree held by clinical pharmacists (i.e., Pharm-D), and a majority, 12 (75.0 %) had heard of a health care professional called a clinical pharmacist. While exploring medical staff attitude toward the availability of a full-time pharmacist in EDs, 13 (81.3 %) of the respondents viewed this favorably while that regarding the role of pharmacists in drug adherence and patient care was viewed less favorably. Fourteen (87.5%) disagreed with giving prescription rights to clinical pharmacists for minor ailments.